Institute of Physiology Czech Academy of Sciences, Prague, Czech Republic.
Pharmacol Res. 2021 Jul;169:105641. doi: 10.1016/j.phrs.2021.105641. Epub 2021 May 2.
Disruption of cholinergic signalling via muscarinic receptors is associated with various pathologies, like Alzheimer's disease or schizophrenia. Selective muscarinic agonists possess therapeutic potential in the treatment of diabetes, pain or Sjögren's syndrome. The orthosteric binding site of all subtypes of the muscarinic receptor is structurally identical, making the development of affinity-based selective agonists virtually impossible. Some agonists, however, are functionally selective; they activate only a subset of receptors or signalling pathways. Others may stabilise specific conformations of the receptor leading to non-uniform modulation of individual signalling pathways (biased agonists). Functionally selective and biased agonists represent a promising approach for selective activation of individual subtypes of muscarinic receptors. In this work we review chemical structures, receptor binding and agonist-specific conformations of currently known functionally selective and biased muscarinic agonists in the context of their intricate intracellular signalling. Further, we take a perspective on the possible use of biased agonists for tissue and organ-specific activation of muscarinic receptors.
胆碱能信号通过毒蕈碱受体的中断与各种病理有关,如阿尔茨海默病或精神分裂症。选择性毒蕈碱激动剂在治疗糖尿病、疼痛或干燥综合征方面具有治疗潜力。所有毒蕈碱受体亚型的正位结合位点在结构上是相同的,这使得基于亲和力的选择性激动剂的开发几乎成为不可能。然而,一些激动剂是功能选择性的;它们仅激活受体的一部分或信号通路。其他激动剂可能稳定受体的特定构象,导致个体信号通路的非均匀调制(偏向激动剂)。功能选择性和偏向激动剂是选择性激活单个毒蕈碱受体亚型的一种有前途的方法。在这项工作中,我们回顾了目前已知的功能选择性和偏向毒蕈碱激动剂的化学结构、受体结合和激动剂特异性构象,以及它们复杂的细胞内信号。此外,我们还从偏向激动剂用于组织和器官特异性激活毒蕈碱受体的角度进行了探讨。